SCHEMBL17355540

SCHEMBL17355540

CCOc1ccc(C(F)(F)Oc2cc(F)c(F)c(F)c2)c(F)c1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR2 P21802 1/20 0.36
▸ KDM1A O60341 2/20 0.35
▸ L3MBTL1 Q9Y468 4/20 0.33
▸ AR P10275 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ RXRA P19793 1/20 0.33
▸ RXRB P28702 1/20 0.33
▸ RXRG P48443 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ CYP1A2 P05177 2/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ TUBB1 Q9H4B7 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ HCRTR1 O43613 4/20 0.32
▸ HCRTR2 O43614 4/20 0.32
▸ HTT P42858 1/20 0.31
▸ S1PR1 P21453 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17355605 0.91 FGFR2 (0.37) FGFR2KDM1AL3MBTL1MAPTRXRA
SCHEMBL17355607 0.87 PTGS2 (0.37) FGFR2L3MBTL1ARMAPTRXRA
SCHEMBL29625867 0.86 FGFR2 (0.31) FGFR2
SCHEMBL29063206 0.86 FGFR2 (0.31) FGFR2
SCHEMBL17369380 0.85 TUBB1 (0.41) ARLMNACYP1A2TUBB1CYP2C9
SCHEMBL18079255 0.84 — —
SCHEMBL17355433 0.84 SENP8 (0.34) RXRARXRBRXRG
SCHEMBL18887795 0.83 AR (0.38) L3MBTL1ARMAPTRXRARXRB
SCHEMBL18079257 0.83 PPARD (0.31) —
SCHEMBL17355624 0.83 RXRA (0.37) FGFR2L3MBTL1MAPTRXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9657229-B2 Liquid crystal compound having difluoromethyleneoxy, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2017-05-23 — — US disclosed
US-20150376502-A1 LIQUID CRYSTAL COMPOUND HAVING DIFLUOROMETHYLENEOXY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2015-12-31 — — US disclosed
EP-2957554-A1 LIQUID-CRYSTALLINE COMPOUND HAVING DIFLUOROMETHYLENEOXY GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC Corporation (JP) 2015-12-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376502-A1 LIQUID CRYSTAL COMPOUND HAVING DIFLUOROMETHYLENEOXY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE C1S, CPNE4, PIEZO1 FGFR2 296/4885KDM1A 1832/4885L3MBTL1 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback